Search

Your search keyword '"Grothey, A"' showing total 27 results
Start Over Author "Grothey, A" Journal onkologie
27 results on '"Grothey, A"'

26. A new chemoembolization protocol in refractory liver metastasis of colorectal cancer--a feasibility study

Author

A. Schlueter, C. Behrmann, Axel Grothey, T. Kegel, Hans-Joachim Schmoll, and Wieland Voigt

Subjects
Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, Colorectal cancer, Metastasis, Advanced colorectal cancer, Folinic acid, Refractory, health services administration, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, In patient, Chemoembolization, Therapeutic, neoplasms, Aged, business.industry, Liver Neoplasms, Hematology, Middle Aged, medicine.disease, digestive system diseases, Oxaliplatin, Irinotecan, Survival Rate, stomatognathic diseases, Treatment Outcome, Disease Progression, Feasibility Studies, Female, business, Colorectal Neoplasms, therapeutics, medicine.drug, Follow-Up Studies
Abstract

In patients with advanced colorectal cancer (CRC) refractory to systemic chemotherapy including 5-fluorouracil (5-FU) / folinic acid (FA), oxaliplatin and irinotecan we assessed the feasibility, toxicity and response to hepatic transcatheter arterial chemoembolization (TACE). At the time of treatment, patients had exclusively or dominantly liver metastasis of CRC.The following protocol was applied via a selective transfemoral hepatic arterial approach: mitomycin C 5 mg/m(2), interferon-alpha2b 4.5 Mio IU, dexamethasone 20 mg mixed with Amilomer DSM 45/25 (Spherex((R))) days 1 and 2 i.a. (bolus), oxaliplatin 50 mg/m(2) (2 h) day 1 i.a., FA 500 mg/m(2) (2 h) day 1 i.v., and 5-FU 1.500 mg/m(2) (24 h) day 1 i.a. Cycles have been repeated at days 15-22. The dose was adjusted according to the pretreatment performance status and elevation of alkaline phosphatase, bilirubin and serum albumin. Treatment was continued until progression or emergence of intolerable toxicity.11 patients received a total number of 43 TACE, with a range of 2-6 per patient. There was no TACE-related mortality. 4 patients died 5, 8, 10 and 11 months after initiation of treatment due to progression of disease. 7 patients are alive at 4+ (n = 2), 5+ (n = 1), 6+ (n = 1), 7+ (n = 1) and 11+ (n = 2) months after start of treatment. Toxicity (CTC) was mild with grade I-II asthenia (n = 10), grade I-II neurotoxicity (n = 5), grade II nausea and/or vomiting (n = 2) and grade II diarrhea (n = 1). Treatment had to be postponed due to grade I thrombocytopenia in 2 patients. No bleeding episodes or obvious infectious complications occurred during treatment intervals. 1 patient experienced an allergic reaction to oxaliplatin which led to exclusion from further therapy. Arterial catheter dislocation occurred in 3 patients. In 10 patients evaluable for response we observed 3 partial responses, 2 minor responses, and 4 times stable disease. Only 1 patient had further progression of disease under treatment.TACE, using a combination of mitomycin C, dexamethasone and interferon-alpha2b mixed with Spherex((R)), followed by oxaliplatin, FA and 5-FU, appears to be an effective and feasible treatment option in the case of liver metastasis of CRC refractory to standard systemic chemotherapy. This treatment is associated with tolerable toxicity, which becomes apparent mainly as asthenia, neurotoxicity or thrombocytopenia. These preliminary data warrant further evaluation for patients with refractory disease and would probably also be of interest for first-line treatment in this patient population.

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results